RENVELA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $25,664 | 8 | 1 |
| 2018 | $266.62 | 14 | 14 |
| 2017 | $132,149 | 2,266 | 1,246 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,829 | 10 | 50.5% |
| Food and Beverage | $40,183 | 2,244 | 25.4% |
| Travel and Lodging | $27,238 | 24 | 17.2% |
| Unspecified | $5,498 | 7 | 3.5% |
| Consulting Fee | $5,332 | 3 | 3.4% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease | GENZYME CORPORATION | $5,498 | 7 |
Top Doctors Receiving Payments for RENVELA — Page 9
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Nephrology | Little Rock, AR | $50.50 | 3 |
| , MD | Nephrology | Dearborn, MI | $50.44 | 3 |
| , MD | Nephrology | Poughkeepsie, NY | $50.34 | 3 |
| , MD | Nephrology | Cincinnati, OH | $50.33 | 4 |
| , MD | Nephrology | Birmingham, AL | $50.29 | 3 |
| , MD | Nephrology | Murfreesboro, TN | $50.13 | 3 |
| , M.D | Nephrology | Phoenix, AZ | $49.92 | 3 |
| Bruce Buchsbaum | — | Des Moines, IA | $49.88 | 3 |
| , M.D | Nephrology | Edgewood, KY | $49.83 | 4 |
| , M.D | Student in an Organized Health Care Education/Training Program | Columbus, OH | $49.57 | 3 |
| , MD | Internal Medicine | Detroit, MI | $49.29 | 2 |
| , M.D | Internal Medicine | Phoenix, AZ | $49.14 | 3 |
| Gerard Tepedino | Nephrology | Manhasset, NY | $49.00 | 3 |
| , D.O | Nephrology | Manhasset, NY | $49.00 | 3 |
| , M.D | Nephrology | Manhasset, NY | $49.00 | 3 |
| , M.D | Nephrology | Fairfax, VA | $48.89 | 3 |
| , M.D | Nephrology | Lafayette, LA | $48.68 | 3 |
| , DO | Nephrology | Philadelphia, PA | $48.63 | 2 |
| , DO | Nephrology | Cherry Hill, NJ | $48.44 | 2 |
| , M.D | Nephrology | Haddonfield, NJ | $48.44 | 2 |
| , MD | Nephrology | Haddonfield, NJ | $48.44 | 2 |
| , M.D | Nephrology | Cherry Hill, NJ | $48.44 | 2 |
| , M.D | Nephrology | Tampa, FL | $48.36 | 2 |
| , M.D | Nephrology | Tampa, FL | $48.36 | 2 |
| , MD | Specialist | Vernon, CT | $48.24 | 2 |
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $131,370
- GENZYME CORPORATION $26,710
Product Information
- Type Drug
- Total Payments $158,080
- Total Doctors 1,251
- Transactions 2,288
About RENVELA
RENVELA is a drug associated with $158,080 in payments to 1,251 healthcare providers, recorded across 2,288 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2019. In 2019, $25,664 was paid across 8 transactions to 1 doctors.
The most common payment nature for RENVELA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,829, 50.5% of total).
RENVELA is associated with 1 research study, including "Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease" ($5,498).